147 related articles for article (PubMed ID: 38700643)
1. Erratum to: Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC.
Rao W; Liu Y; Li Y; Guo L; Qiu T; Dong L; Ying J; Li W
Front Med; 2024 Apr; ():. PubMed ID: 38700643
[No Abstract] [Full Text] [Related]
2. Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC.
Rao W; Liu Y; Li Y; Guo L; Qiu T; Dong L; Ying J; Li W
Front Med; 2023 Jun; 17(3):493-502. PubMed ID: 37010729
[TBL] [Abstract][Full Text] [Related]
3. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
[TBL] [Abstract][Full Text] [Related]
5. TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.
Robesova B; Bajerova M; Liskova K; Skrickova J; Tomiskova M; Pospisilova S; Mayer J; Dvorakova D
Lung Cancer; 2014 Jul; 85(1):25-30. PubMed ID: 24792336
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
7. Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC.
Song Z; Lian S; Mak S; Chow MZ; Xu C; Wang W; Keung HY; Lu C; Kebede FT; Gao Y; Cheuk W; Cho WCS; Yang M; Zheng Z
J Thorac Oncol; 2022 Feb; 17(2):264-276. PubMed ID: 34626839
[TBL] [Abstract][Full Text] [Related]
8. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
[TBL] [Abstract][Full Text] [Related]
9. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method.
Maus MK; Stephens C; Zeger G; Grimminger PP; Huang E
Int J Biomed Sci; 2012 Mar; 8(1):1-6. PubMed ID: 23675251
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions.
Parvaresh H; Roozitalab G; Golandam F; Behzadi P; Jabbarzadeh Kaboli P
Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397899
[No Abstract] [Full Text] [Related]
12. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
[TBL] [Abstract][Full Text] [Related]
13. Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021.
Roberts TJ; Kesselheim AS; Avorn J
JAMA Netw Open; 2023 Jan; 6(1):e2252562. PubMed ID: 36696113
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
[TBL] [Abstract][Full Text] [Related]
15. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
16. Catalog of 5' Fusion Partners in
Ou SI; Zhu VW; Nagasaka M
JTO Clin Res Rep; 2020 Mar; 1(1):100015. PubMed ID: 34589917
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
18. ALK and NSCLC: Targeted therapy with ALK inhibitors.
Hallberg B; Palmer RH
F1000 Med Rep; 2011; 3():21. PubMed ID: 22076124
[TBL] [Abstract][Full Text] [Related]
19. A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC.
Sampson J; Ju HM; Song JY; Fry AM; Bayliss R; Choi J
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159046
[TBL] [Abstract][Full Text] [Related]
20. HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors.
Kim M; Ju HM; Song JY; Sampson J; Bayliss R; Choi J
Transl Lung Cancer Res; 2024 Feb; 13(2):321-333. PubMed ID: 38496685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
